Application error: a client-side exception has occurred (see the browser console for more information).

Global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for ...

Chapter 11 bankruptcy filings in 2024 by biotech companies and other healthcare firms continued to rise after a steady ...

PEARL RIVER, N.Y. — PEARL RIVER, N.Y. — Acorda Therapeutics Inc. (ACORQ) on Tuesday reported a loss of $27.4 million in its first quarter. On a per-share basis, the Pearl River, New York-based ...

PEARL RIVER, N.Y. (AP) — PEARL RIVER, N.Y. (AP) — Acorda Therapeutics Inc. (ACORQ) on Tuesday reported a loss of $27.4 million in its first quarter. On a per-share basis, the Pearl River, New ...

Nepicastat hydrochloride is under clinical development by Acorda Therapeutics and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% ...

#GMAIntegratedNews #KapusoStream Breaking news and stories from the Philippines and abroad: GMA Integrated News Portal: http://www.gmanews.tv Facebook: http://www ...

Acorda Therapeutics, a biotech firm celebrated for pioneering treatments in the fight against Parkinson’s and Multiple Sclerosis, has hit a rough patch. On April 1, they filed for Chapter 11 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...